Molecular determinants of local anesthetic action of beta-blocking drugs: Implications for therapeutic management of long QT syndrome variant 3

Journal of Molecular and Cellular Cardiology

Volumn 48, Issue 1, 2010, Pages 246-253

  Bankston, John R ^a   Kass, Robert S ^a  

^a Columbia University ^*  (United States)

Author keywords

Beta blockers; Local anesthetics; Long QT syndrome; Na+ channels

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CARVEDILOL; LOCAL ANESTHETIC AGENT; METOPROLOL; MEXILETINE; PROPRANOLOL; SODIUM CHANNEL; SODIUM CHANNEL NAV1.5;

ARTICLE; CONTROLLED STUDY; DRUG BINDING SITE; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENTIATION; EMBRYO; FREQUENCY MODULATION; GENE MUTATION; HUMAN; HUMAN CELL; LONG QT SYNDROME; LONG QT SYNDROME 3; MOLECULAR INTERACTION; PRIORITY JOURNAL; PROTEIN FUNCTION; SODIUM CURRENT;

ADRENERGIC BETA-ANTAGONISTS; ANESTHETICS, LOCAL; CARBAZOLES; CELL LINE; ELECTROPHYSIOLOGY; HEART; HUMANS; LONG QT SYNDROME; METOPROLOL; PROPANOLAMINES; PROPRANOLOL; SODIUM CHANNELS;

EID: 73049100392     PISSN: 00222828     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.yjmcc.2009.05.012     Document Type: Article

References (40)

1. Kass R.S., and Moss A.J. Mutation-specific pharmacology of the long QT syndrome. Handb. Exp. Pharmacol. 171 (2006) 287-304
2. Chen L., Marquardt M.L., Tester D.J., Sampson K.J., Ackerman M.J., and Kass R.S. Mutation of an A-kinase-anchoring protein causes long-QT syndrome. Proc. Natl. Acad. Sci. U. S. A. (2007 Dec 19)
3. Vatta M., Ackerman M.J., Ye B., Makielski J.C., Ughanze E.E., Taylor E.W., et al. Mutant caveolin-3 induces persistent late sodium current and is associated with long-QT syndrome. Circulation 114 20 (2006 Nov 14) 2104-2112
4. Splawski I., Shen J., Timothy K.W., Lehmann M.H., Priori S., Robinson J.L., et al. Spectrum of mutations in long-QT syndrome genes. KVLQT1, HERG, SCN5A, KCNE1, and KCNE2. Circulation 102 10 (2000 Sep 5) 1178-1185
5. Napolitano C., Priori S.G., Schwartz P.J., Bloise R., Ronchetti E., Nastoli J., et al. Genetic testing in the long QT syndrome: development and validation of an efficient approach to genotyping in clinical practice. Jama 294 23 (2005 Dec 21) 2975-2980
6. Moss A.J., Zareba W., Hall W.J., Schwartz P.J., Crampton R.S., Benhorin J., et al. Effectiveness and limitations of beta-blocker therapy in congenital long-QT syndrome. Circulation 101 6 (2000 Feb 15) 616-623
7. Vincent G.M., Schwartz P.J., Denjoy I., Swan H., Bithell C., Spazzolini C., et al. High efficacy of beta-blockers in long-QT syndrome type 1: contribution of noncompliance and QT-prolonging drugs to the occurrence of beta-blocker treatment "failures". Circulation 119 2 (2009 Jan 20) 215-221
8. Schwartz P.J., Priori S.G., Spazzolini C., Moss A.J., Vincent G.M., Napolitano C., et al. Genotype-phenotype correlation in the long-QT syndrome: gene-specific triggers for life-threatening arrhythmias. Circulation 103 1 (2001 Jan 2) 89-95
9. Bennett P.B., Yazawa K., Makita N., and George Jr. A.L. Molecular mechanism for an inherited cardiac arrhythmia. Nature 376 6542 (1995 Aug. 24) 683-685
10. Clancy C.E., Tateyama M., and Kass R.S. Insights into the molecular mechanisms of bradycardia-triggered arrhythmias in long QT-3 syndrome. J. Clin. Invest. 110 9 (2002 Nov) 1251-1262
11. + channel blockade and to increases in heart rate. Implications for gene-specific therapy. Circulation 92 12 (1995 Dec 15) 3381-3386
12. Moss A.J., Windle J.R., Hall W.J., Zareba W., Robinson J.L., McNitt S., et al. Safety and efficacy of flecainide in subjects with Long QT-3 syndrome (DeltaKPQ mutation): a randomized, double-blind, placebo-controlled clinical trial. Ann. Noninvasive Electrocardiol. 10 4 Suppl. (2005 Oct) 59-66
13. Nagatomo T., January C.T., and Makielski J.C. Preferential block of late sodium current in the LQT3 DeltaKPQ mutant by the class I(C) antiarrhythmic flecainide. Mol. Pharmacol. 57 1 (2000 Jan) 101-107
14. Morales Aguilera A., and Vaughanwilliams E.M. The effects on cardiac muscle of beta-receptor antagonists in relation to their activity as local anaesthetics. Br. J. Pharmacol. Chemother. 24 (1965 Apr) 332-338
15. Murray K.T., Reilly C., Koshakji R.P., Roden D.M., Lineberry M.D., Wood A.J., et al. Suppression of ventricular arrhythmias in man by d-propranolol independent of beta-adrenergic receptor blockade. J. Clin. Invest. 85 3 (1990 Mar) 836-842
16. Sada H., and Ban T. Frequency-dependent block of nerve conduction by beta-adrenergic blocking agents. Arch. Int. Pharmacodyn. Ther. 254 1 (1981 Nov) 134-144
17. Duff H.J., Mitchell L.B., and Wyse D.G. Antiarrhythmic efficacy of propranolol: comparison of low and high serum concentrations. J. Am. Coll. Cardiol. 8 4 (1986 Oct) 959-965
18. Ahrens-Nicklas R.C., Clancy C.E., and Christini D.J. Re-evaluating the efficacy of {beta}-adrenergic agonists and antagonists in long QT-3 syndrome through computational modelling. Cardiovasc. Res. (2009 Mar 24)
19. Abriel H., Cabo C., Wehrens X.H., Rivolta I., Motoike H.K., Memmi M., et al. Novel arrhythmogenic mechanism revealed by a long-QT syndrome mutation in the cardiac Na(+) channel. Circ. Res. 88 7 (2001 Apr 13) 740-745
20. Liu H., Tateyama M., Clancy C.E., Abriel H., and Kass R.S. Channel openings are necessary but not sufficient for use-dependent block of cardiac Na(+) channels by flecainide: evidence from the analysis of disease-linked mutations. J. Gen. Physiol. 120 1 (2002 Jul) 39-51
21. Bankston J.R., Yue M., Chung W., Spyres M., Pass R.H., Silver E., et al. A novel and lethal de novo LQT-3 mutation in a newborn with distinct molecular pharmacology and therapeutic response. PLoS ONE 2 12 (2007) e1258
22. Rivolta I., Abriel H., Tateyama M., Liu H., Memmi M., Vardas P., et al. Inherited Brugada and long QT-3 syndrome mutations of a single residue of the cardiac sodium channel confer distinct channel and clinical phenotypes. J. Biol. Chem. 276 33 (2001 Aug 17) 30623-30630
23. Fredj S., Sampson K.J., Liu H., and Kass R.S. Molecular basis of ranolazine block of LQT-3 mutant sodium channels: evidence for site of action. Br. J. Pharmacol. 148 1 (2006 May) 16-24
24. Ragsdale D.S., McPhee J.C., Scheuer T., and Catterall W.A. Molecular determinants of state-dependent block of Na+ channels by local anesthetics. Science 265 5179 (1994 Sep 16) 1724-1728
25. Liu H., Atkins J., and Kass R.S. Common molecular determinants of flecainide and lidocaine block of heart Na(+) channels: evidence from experiments with neutral and quaternary flecainide analogues. J. Gen. Physiol. 121 3 (2003) 199-214 2003/03//
26. Valdivia C.R., Chu W.W., Pu J., Foell J.D., Haworth R.A., Wolff M.R., et al. Increased late sodium current in myocytes from a canine heart failure model and from failing human heart. J. Mol. Cell. Cardiol. 38 3 (2005 Mar) 475-483
27. Noble D., and Noble P.J. Late sodium current in the pathophysiology of cardiovascular disease: consequences of sodium-calcium overload. Heart 92 Suppl 4 (2006 Jul) iv1-iv5
28. Tenero D.M., Henderson L.S., Baidoo C.A., Harter A.H., Campanile A.M., Danoff T.M., et al. Pharmacokinetic properties of a new controlled-release formulation of carvedilol. Am. J. Cardiol. 98 7A (2006 Oct 2) 5L-16L
29. Talbert R.L. Pharmacokinetics and pharmacodynamics of beta blockers in heart failure. Heart Fail. Rev. 9 2 (2004 Apr) 131-137
30. Priori S.G., Napolitano C., Schwartz P.J., Grillo M., Bloise R., Ronchetti E., et al. Association of long QT syndrome loci and cardiac events among patients treated with beta-blockers. Jama 292 11 (2004 Sep 15) 1341-1344
31. Nuyens D., Stengl M., Dugarmaa S., Rossenbacker T., Compernolle V., Rudy Y., et al. Abrupt rate accelerations or premature beats cause life-threatening arrhythmias in mice with long-QT3 syndrome. Nat. Med. 7 9 (2001 Sep) 1021-1027
32. Ragsdale D.S., McPhee J.C., Scheuer T., and Catterall W.A. Common molecular determinants of local anesthetic, antiarrhythmic, and anticonvulsant block of voltage-gated Na+ channels. Proc. Natl. Acad. Sci. U. S. A. 93 17 (1996 Aug 20) 9270-9275
33. Ahern C.A., Eastwood A.L., Dougherty D.A., and Horn R. Electrostatic contributions of aromatic residues in the local anesthetic receptor of voltage-gated sodium channels. Circ. Res. 102 1 (2008 Jan 4) 86-94
34. Colquhoun D. Binding, gating, affinity and efficacy: the interpretation of structure-activity relationships for agonists and of the effects of mutating receptors. Br. J. Pharmacol. 125 5 (1998 Nov) 924-947
35. Dupuis D.S., Klaerke D.A., and Olesen S.P. Effect of beta-adrenoceptor blockers on human ether-a-go-go-related gene (HERG) potassium channels. Basic Clin. Pharmacol. Toxicol. 96 2 (2005 Feb) 123-130
36. Yao X., McIntyre M.S., Lang D.G., Song I.H., Becherer J.D., and Hashim M.A. Propranolol inhibits the human ether-a-go-go-related gene potassium channels. Eur. J. Pharmacol. 519 3 (2005 Sep 20) 208-211
37. Saranteas T., Mourouzis C., Koumoura F., and Tesseromatis C. Effects of propranolol or paracetamol on lidocaine concentrations in serum and tissues. J. Oral Maxillofac. Surg. 61 5 (2003 May) 604-607
38. Mayer T., and Specht U. Propranolol in startle induced epileptic seizures. J. Neurol. Neurosurg. Psychiatry 58 3 (1995 Mar) 382-383
39. Renshaw P.F., Ford H.E., and Brotman A.W. Possible synergistic anticonvulsant effect of propranolol and carbamazepine. Am. J. Psychiatry 147 12 (1990 Dec) 1687-1688
40. Undrovinas A.I., Maltsev V.A., and Sabbah H.N. Repolarization abnormalities in cardiomyocytes of dogs with chronic heart failure: role of sustained inward current. Cell. Mol. Life Sci. 55 3 (1999 Mar) 494-505